Moderna and Immatics Announce Strategic Multi-Platform Collaboration

Develop Innovative Oncology Therapeutics

13-Sep-2023 - Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational ...

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

27-Jul-2023 - Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced that Bristol Myers Squibb has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a ...

Immatics Receives Financing to Develop T-Cell Receptor Based Immunotherapies

05-Oct-2017 - Immatics, company in the field of cancer immunotherapy, announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. This latest financing ...

immatics receives €22 million final tranche of Series D fundraising

17-Jul-2014 - immatics biotechnologies GmbH announced that it has received €22m to complete a Series D financing round. The Company received €12m in October 2013 as an initial tranche of the total €34m funding round. The Series D funding was supported by existing investors including dievini Hopp Biotech ...

immatics and Roche sign cancer vaccine and immunotherapy collaboration

Collaboration spans the discovery, development and commercialisation of cancer vaccines and other cancer immunotherapies in gastric, lung and prostate cancer

18-Nov-2013 - immatics biotechnologies GmbH and Roche announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics. The agreement will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide ...

immatics appoints Peter Chambré as Chairman

15-Nov-2012 - immatics biotechnologies GmbH announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will ...

Kidney Cancer Vaccine Successful in Clinical Trials

31-Jul-2012 - Researchers at the University of Tübingen and immatics biotechnologies GmbH – a start-up by Tübingen scientists – have published the results of two clinical studies using the kidney-cancer vaccine IMA901 in the latest edition of Nature Medicine. IMA901 is used to treat patients with cancer of the ...

immatics wins 2012 TiE50 Award

30-May-2012 - immatics biotechnologies GmbH announced that it has been named a 2012 TiE50 winner. These awards recognize entrepreneurship, innovation and management excellence within the life sciences, software, internet, mobile and energy sectors. immatics was chosen from more than 2,100 technology ...

immatics appoints Dr Rainer Kramer as Chief Business Officer

16-Apr-2012 - immatics biotechnologies GmbH announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect. In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic ...

First patients are vaccinated in IMPRINT, immatics’ pivotal Phase III trial with IMA901 in patients with renal cell carcinoma (RCC)

17-Jun-2011 - immatics biotechnologies GmbH announced that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).The trial is designed to demonstrate the overall survival benefit of ...